In this webinar, we take an in-depth exploration of functional organoids and their pivotal role in disease modeling, with a particular focus on Rett Syndrome—a progressive neurodevelopmental disorder linked to mutations in the MECP2 gene. This session will guide you through the comprehensive process of developing a disease model, beginning with induced pluripotent stem cell (iPSC) expansion and organoid generation, and culminating in high-throughput screening techniques. Discover how patient-derived neural organoids can be leveraged alongside functional phenotypic screening to investigate target-specific disease biology, formulate therapeutic hypotheses, and enhance pre-clinical drug discovery efforts.
Nicholas Coungeris, Research Scientist II
Nick Coungeris is a Research Scientist at 28bio specializing in utilizing iPSC-derived brain organoid technology for disease modeling and drug screening. Specifically, he has focused on expanding the capabilities of 28bio's CNS-3D organoids to include multiple cell types, various genetic and induced disease models and continued client research.
Andrew LaCroix is a Lead Scientist at 28bio specializing in the development of iPSC-derived brain organoid models and their applications to preclinical safety and efficacy testing. Specifically, he has focused on predictive neurotoxicity assays and human-first drug discovery to reduce clinical failure rates and improve patient outcomes.
